Sustained Hedgehog (HH) signaling is implicated in basal cell carcinoma of the skin and other types of cancer. Here we show that GLI1 and GLI2, the main transcriptional activators of the HH pathway, directly regulate expression of the activator protein 1 (AP-1) family member JUN, a transcription factor controlling keratinocyte proliferation and skin homeostasis. Activation of the JUN promoter by GLI is dependent on a GLI-binding site and the AP-1 sites known to be involved in self-activation of JUN. Transcription of JUN is greatly enhanced in the presence of GLI and requires activated JUN protein.
Introduction
The GLI transcription factors are the main mediators of the Hedgehog (HH) signal and are important during development, tissue homeostasis, regeneration and stem cell maintenance (reviewed in Beachy et al., 2004; Ingham and McMahon, 2001 ; Pasca di Magliano and Hebrok, 2003; Ruiz i Altaba et al., 2007) . The importance of the HH/GLI pathway and its components in regulating proliferation and differentiation is reflected in the growing number of malignancies of skin, brain, pancreas, prostate and lung, which have been linked to ectopic expression of activator GLI proteins (reviewed in Evangelista et al., 2006; Hebrok, 2003; Pasca di Magliano and Hebrok, 2003; Rubin and de Sauvage, 2006; Ruiz i Altaba et al., 2007; Stecca and Ruiz i Altaba, 2002; Vezina and Bushman, 2007) . Normally, binding of HH to its receptor PTCH leads to the stabilization and activation of full-length GLI proteins (GLIact) through the transmembrane signal transducer smoothened (SMOH). Activated GLI is, however, found not only in the presence of ligand, but also when the pathway is activated by oncogenic events: inactivating mutations in PTCH (Hahn et al., 1996; Johnson et al., 1996) and activating mutations in SMOH cause basal cell carcinoma (BCC) of the skin (Xie et al., 1998) , and mouse models of BCC have been created using transgenic mice expressing GLI1 or GLI2 in basal keratinocytes of the skin (Grachtchouk et al., 2000; Nilsson et al., 2000; Sheng et al., 2002) .
In the absence of HH, the GLI proteins are inactivated and/or processed into repressor forms (GLIrep) . Although all GLI proteins bind the same consensus sequence with their highly conserved zincfinger DNA-binding domain (Kinzler and Vogelstein, 1990; Hallikas et al., 2006) , the functional consequences may differ. GLI1 and GLI2 mostly act as activators of transcription whereas proteolytically processed GLI3 mainly acts as repressor. In contrast to GLI2 and GLI3, GLI1 is not directly activated by HH signaling but is itself a transcriptional target gene of GLI2 and GLI3. A wealth of data has shown that stability, cellular localization and transcriptional activity of GLI proteins are regulated by several phosphorylation events and by other interacting proteins (reviewed in Hooper and Scott, 2005; Huangfu and Anderson, 2006; Ingham and McMahon, 2001; Kasper et al., 2006a) .
Recently, it has been shown that GLI activity is also responsive to other signaling pathways. GLI target gene activation and specificity was shown to be affected by PKCd (Riobo et al., 2006a; Lauth et al., 2007) , Akt/ PI3K (Riobo et al., 2006b) , RAS/MEK/ERK (Pasca di Magliano et al., 2006; Stecca et al., 2007; Neill et al., 2008) and EGF signaling (Bigelow et al., 2005; Kasper et al., 2006b; Mimeault et al., 2007) . However, the integration of different upstream signals by co-activators and other modulators on GLI target gene promoters is still far from clear.
JUN belongs to a protein family that forms homodimers or heterodimers with members of the FOS, the activating transcription factor (ATF) and the musculoaponeurotic fibrosarcoma families, constituting the activator protein 1 (AP-1) complex (reviewed in Hess et al., 2004; Mechta-Grigoriou et al., 2001) . JUN acts primarily as activator of transcription and is regulated at different levels including activation of its own transcription thus creating a positive feedback loop (Angel et al., 1988a) . Phosphorylation by JUN N-terminal kinase (JNK), a target of mitogen-activated protein kinase signaling, is crucial for full transcriptional activity of JUN (reviewed in Weston and Davis, 2007) . Activated JUN mediates the response to signaling caused by tumor promoters, stress, UV irradiation and wounding. It is important in tumorigenesis by influencing cell proliferation, survival, transformation and invasion (reviewed in Eferl and Wagner, 2003; Johnson and Nakamura, 2007; Maeda and Karin, 2003; Yates and Rayner, 2002; Zenz and Wagner, 2006) . In mice the effects of loss of Jun or loss of Jun activation are highly dependent on cell type and tissue (reviewed in Jochum et al., 2001) . Jun is essential in embryonic development (Johnson et al., 1993) , though knocking out Jun in keratinocytes results in normal skin architecture. Cultured primary Jun À/À keratinocytes, however, show reduced proliferation (Zenz et al., 2003) . An important contribution of JUN to cellular proliferation is the transcriptional activation of cyclin D1 (CCND1) in keratinocytes and other positive regulators of cell-cycle progression as well as inhibition of negative regulators (reviewed in Zenz and Wagner, 2006) . The importance of Jun in tumor initiation was shown in a tumor prone mouse model. Papillomas form in mice overexpressing the activated son of sevenless (SOS) gene under the keratin 5 promoter leading to Jun activation through the Ras pathway . In contrast, only small tumors formed in the absence of Jun (Zenz et al., 2003) and tumor formation was also impaired in mice expressing mutant Jun proteins that cannot be phosphorylated and activated by JNK (Behrens et al., 1999 .
Here we show that JUN is a direct target of GLI1 and GLI2 in human keratinocytes. Cooperative activation of JUN by GLI and JUN is strongly dependent on one GLI-binding site and the presence of the known AP-1 sites. Physical interaction between JUN and GLI2 depends on JNK-mediated phosphorylation of JUN. Decreased JUN expression reduces the cell-cycle-promoting activity of GLI and a subset of its target genes that are jointly regulated by HH/GLI and JUN.
Results

JUN expression is increased in response to GLI in human keratinocytes
We investigated the influence of HH/GLI signaling on the expression of AP-1 family members in human keratinocytes using HaCaT cell lines expressing either GLI1 (GLI1HaCaT) (Eichberger et al., 2006) or an activator form of GLI2 (GLI2act) (GLI2actHaCaT) (Regl et al., 2004a) under doxycycline control. qRT-PCR showed that JUN mRNA is already elevated 12 h (fourfold) after GLI2act induction and increases strongly at later time points (up to 16-fold at 72 h for GLI2act) (Figure 1a) . In HaCaT cells expressing GLI1, JUN mRNA levels are only moderately increased compared to GLI2act (Figure 1a) , even though levels of the GLI target PTCH (Figure 1b) are comparable. The same is true for GLI1 and GLI2act protein levels (Figures 1c and d , upper panels). We found no significant change in mRNA levels of the AP-1 components JUNB and JUND and FOS, FOSB, FRA1 and FRA2 (Supplementary Figure  S1) . Stimulation of JUN expression in GLI1HaCaT and GLI2actHaCaT cells was also observed on the protein level as shown by western blot (Figures 1c and d) and Nterminal phosphorylation at Ser63 of JUN protein is detectable in both cell lines, suggesting that transcriptionally active JUN is present (Smeal et al., 1992) . In agreement with the qRT-PCR results, JUN protein expression is weaker and delayed in GLI1HaCaT compared to GLI2actHaCaT cells, where a distinct signal is already detectable 12 h after induction. To exclude that JUN induction by GLI is an unusual response restricted to the HaCaT cell line, we retrovirally transduced the human keratinocyte cell line N/TERT-1 (Dickson et al., 2000) and also primary human foreskin keratinocytes (pFSK) with either enhanced green fluorescent protein (EGFP) or human GLI2act. At 96 h after infection, elevated levels of JUN mRNA and protein were detectable for GLI2act expression compared to the EGFP expressing control in both cell types (Figures 1e and f) .
Having shown that expression of GLI1 and GLI2act in cultured keratinocytes leads to an increase in JUN mRNA and protein, we investigated JUN expression in BCC, which shows strong expression of HH pathway components PTCH, GLI1 and GLI2 (Hahn et al., 1996; Johnson et al., 1996; Ghali et al., 1999; Regl et al., 2002) . We measured the mRNA levels of JUN, GLI1, GLI2 and PTCH by qRT-PCR in samples of human BCC (n ¼ 6) and normal human skin (n ¼ 3) (Figure 2a) . BCC samples showed characteristic high expression of GLI1, GLI2 and PTCH and also significantly increased JUN mRNA levels compared to healthy skin (Figure 2a ). Immunohistochemical staining of JUN protein on sections of paraffin-embedded human BCC samples confirmed qRT-PCR results (Figure 2b ). Strong and specific nuclear staining was found throughout the tumor islands pointing to transcriptionally active JUN protein in accordance with previous studies (Zhang et al., 2006) . No staining was found in the surrounding stroma. These results support regulation of JUN expression by HH/GLI signaling in vivo.
The JUN promoter contains at least one functional GLI-binding site Because JUN transcription is activated by GLI, we searched for putative GLI-binding sites in the promoter region of human JUN. Using ScanACE (Roth et al., 1998) we identified a cluster of five potential GLIbinding sites (GLIBS1-5) located between À785 and À503 upstream of the transcription start site (according to NM_002228) and one isolated potential binding site at position þ 332 (BS6). All binding sites differ from the consensus sequence (Kinzler and Vogelstein, 1990) by two nucleotide substitutions (Figure 3a ). To test these putative GLI-binding sites, we cloned a 1243 bp fragment (À829 bp to þ 414 bp) of the JUN promoter comprising the predicted GLI-binding sites and the known AP-1-binding sites JUNBS1 and JUNBS2 (Angel et al., 1988b; Stein et al., 1992) in a luciferase reporter vector (JUNprom) (Figure 3a) . Transcription of luciferase from this reporter can be activated by GLI1 and GLI2act (Figure 3b ). Consistent with qRT-PCR and western blot results (Figure 1 ), activation by GLI1 is significantly weaker compared to GLI2act. Fulllength GLI2, which is known to have reduced activation potential compared to the N-terminally truncated form GLI2act (Roessler et al., 2005) , activates transcription to a similar level as GLI1. The N-terminally truncated form of GLI3 (GLI3act), previously described as an activator (Sasaki et al., 1999) , did not induce detectable luciferase transcription (Figure 3b ). To assess the importance of the predicted GLI-binding sites (Figure 3a ), all sites were inactivated individually or in different combinations by mutation at essential positions (see Materials and methods section) (Figure 3c ). Only mutation of binding site 3 (GLIBS3) abolished reporter gene activity (Figure 3c ), whereas mutation of the binding sites 1 (GLIBS1m), 2 (GLIBS2m), 4 (GLIBS4m), 5 (GLIBS5m) or 6 (GLIBS6m) alone or in different combinations (GLIBS1to4m, GLIBS3to4m, GLIBS1to5m or GLIBS1to6m) (Figure 3c ) did not result in significant reduction of promoter activity. We therefore conclude that BS3 is essential for transcriptional activation of the JUN promoter by GLI. Because BS3 differs considerably from the published GLI consensus binding site, we tested the binding of a recombinant purified GLI zinc-finger domain protein to BS3 in an electrophoretic mobility shift assay (EMSA) (Figure 3d ). The GLI zinc-finger domain specifically binds to BS3 in this assay as shown by competition with excess of BS3 itself or the consensus sequence (Cons), but not with mutated oligonucleotide (mut) or unspecific competitor poly dI-dC ( Figure 3d) . A multiple sequence alignment shows that GLIBS3 is completely conserved in primates (data not shown), cattle and cat, rat and mouse share two substitutions (Supplementary Figure  S5) . In addition mouse misses one nucleotide and it is conceivable that this might be a sequencing error (Supplementary Figure S5) . All potential GLI-binding sites shown to be nonfunctional (Figure 3c) are not conserved. Together these results identified BS3 as a functional GLI-binding site that is essential for activation of JUN by GLI in human keratinocytes.
Jun promoter activity is strongly enhanced by combinatorial action of GLI and JUN itself The fact that JUN is a target of itself and also of GLI implies an interaction between those factors. Using JUN promoter luciferase reporter constructs carrying mutations in either GLIBS3 (Figure 3c ) or the JUN-binding sites JUNBS1 and JUNBS2 (Figure 3a) , we found that activation of the JUN promoter by GLI1 and GLI2act not only depends on the presence of GLIBS3 but also on both JUN sites. Mutation of JUNBS1 and JUNBS2 (JUN_JUNBSm, Figure 4a ) strongly reduces the activation potential of both GLI transcription factors compared to the wild-type JUN promoter (JUNprom) and, as expected, abolished the activation by JUN. In contrast, mutation of BS3 (JUN_GLIBS3) only affects the activation of the JUN promoter by GLI but not by JUN (Figure 4a ). The cooperative interaction of JUN and GLI was confirmed using UV irradiation to activate endogenous JUN in HaCaT cells. UV light has been reported to activate JNK leading to hyperphosphorylation and activation of JUN (Hibi et al., 1993; Figure 4b, inset) . We therefore irradiated HaCaT cells co-transfected with GLI1 or GLI2act and JUN promoter Luciferase reporter constructs used in (a) were co-transfected with GLI1 or GLI2act expression constructs or empty vector (p4TO) in HaCaT cells. At 48 h after transfection cells were exposed to a short UV light pulse and reporter activity was measured after additional 2 h of cultivation and compared to UV untreated samples. The phosphorylation state of JUN was controlled by western blot using a phospho-specific JUN antibody (pJUN) (inset). (c) Chromatin immunoprecipitation (ChIP) demonstrates specific binding of GLI1 or GLI2 and JUN to the JUN promoter. Chromatin isolated from GLI1HaCaT or GLI2actHaCaT cells was precipitated with either specific antibody (aGLI1, aGLI2, aJUN) or species matched normal IgG (nIgG). Signals for DNA fragments spanning the functional GLIbinding site (GLIBS) or activator protein 1 (AP-1)-binding sites (JUNBS) as indicated in the drawing were only detected in the specific precipitates. No amplification was observed in controls (nIgG) and for a 284 bp fragment of the human RPLP0 promoter.
Cooperative target gene regulation by GLI and JUN S Laner-Plamberger et al constructs to efficiently induce JUN activation (Figure 4b ). UV irradiation in the absence of GLI leads to a twofold increase in promoter activity (JUNprom) regardless of the presence of GLIBS3 (JUN_GLIBS3m) whereas UV irradiation has no effect in the absence of JUNBS (JUN_JUNBSm, Figure 4b ). When the cells are irradiated in the presence of GLI, a dramatic increase in wild-type promoter (JUNprom) activity was observed demonstrating a synergistic interaction between GLI and JUN. Chromatin immunoprecipitation (ChIP) extended this result to the physical presence of the two transcription factors on the JUN promoter (Figure 4c ). In GLI1HaCaT (upper panels) and GLI2actHaCaT (lower panels) cells, JUN and GLI were found at their respective binding sites as demonstrated by specific precipitation of DNA fragments spanning either GLIBS3 (fragment GLIBS) or the two JUN-binding sites (fragment JUNBS).
Modulation of GLI target gene expression by JUN
We next asked whether other GLI target genes are regulated similarly. We therefore stably knocked down JUN in GLI2actHaCaT cells by a retroviral shorthairpin RNA (shRNA) approach ( Supplementary Figure S2) . mRNA samples of GLI2actHaCaT cells stably transduced with ctrlshRNA or specific JUNshRNA and induced for 72 h ( þ GLI2act) or uninduced controls (ÀGLI2act) were analysed on cDNA filter arrays (Regl et al., 2004a; Eichberger et al., 2006) . GLI2act transgene mRNA and protein levels were unaffected by the JUNshRNA as determined by qRT-PCR (Table 1 , group I) and western blot (Supplementary Figure S2) . Selected genes regulated by both GLI2act and JUN were further validated by qRT-PCR (Table 1) . We found that JUN expression is required for the upregulation of a subset of GLI target genes only ( 
For other genes activation in the presence of JUN and GLI may be additive as shown for WNT11, CCND1, IKBKE and FYN (Table 1 , group II). To extend these findings to non-HaCaT keratinocytes, we used N/ TERT-1 keratinocytes that are reported to have growth and differentiation characteristics similar to primary keratinocytes (Dickson et al., 2000) . Cells were transduced with LL3.7 lentivirus expressing EGFP-tagged GLI2act (LL3.7-GLI2act) or EGFP (LL3.7) (control) (Kasper et al., 2007) followed by retroviral transduction with JUNshRNA or ctrlshRNA. mRNA levels of selected genes from Table 1 were analysed by qRT-PCR ( Figure 5 ). As in HaCaT cells, knockdown of JUN results in strongly reduced expression of GLI2act/JUN target genes without significant influence on canonical HH target genes such as GLI1 ( Figure 5 ). Whether all genes listed in Table 1 are directly regulated by GLI cannot be deduced from the qRT-PCR data, though for some, direct regulation by GLI and JUN was shown by luciferase reporter assays (Supplementary Figure S3) . Others have previously been described as direct GLI targets (footnote a, Table 1 ) or direct AP-1 targets (footnote b, Table 1 ). A similar experiment was conducted in HaCaT cells expressing GLI1 (GLI1Ha-CaT) and some genes selected from Table 1 , group II also showed cooperative activation though quantitative differences to GLI2act were observed (Supplementary Table S5 ). In summary, these data point to cooperative regulation between GLI and JUN on a subset of HH/GLI target genes in epidermal cells, suggesting a novel mechanism of modulating HH/GLI target gene expression.
Physical interaction between GLI2 and JUN requires phosphorylation of JUN Cooperative target gene regulation may be associated with physical interaction between GLI and JUN. (Angel et al., 1988b; Gramigni et al., 1998; Hayakawa et al., 2004; Herber et al., 1994) .
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Co-immunoprecipitation (CoIP) of GLI1 or GLI2act and JUN protein from inducible HaCaT cells expressing MYC-tagged GLI1 (MGLI1HaCaT) or MYC-tagged
GLI2act (MGLI2actHaCaT) detected interaction of endogenous JUN with GLI2act but not GLI1 (Figure 6a ). We confirmed this surprising observation in transiently transfected human embryonic kidney (HEK) cells. HEK cells were co-transfected with either MYC-tagged GLI1 (MGLI1) or MYC-tagged GLI2act (MGLI2act) together with FLAG-tagged JUN (FJUN) expression constructs or empty expression vector (pCMV). FLAG-tagged SUFU (FSUFU), which should interact with both GLI1 and GLI2, was used as positive control (Pearse et al., 1999) . Again, we detected only interaction of JUN and GLI2act but not of JUN and GLI1 (Figure 6b ), although both GLI1 and GLI2act showed specific interaction with SUFU. Because phosphorylation of JUN by JNK is important in protein-protein interactions (Bannister et al., 1995) , we investigated the effect of JUN phosphorylation on the interaction of JUN with GLI2act by CoIP in the presence of SP600125 a potent inhibitor of JNK. Interaction of JUN and GLI2act was strongly diminished, although protein levels in the input were unchanged compared to controls (Figures 6c and d; Supplementary Figure S4 ). This was observed in transiently transfected HEK cells (Figure 6d ) as well as in MGLI2actHaCaT cells (Figure 6c ). The ability of phosphorylated JUN to interact with cofactors in MGLI2actHaCaT cells was verified using CBP, which has previously been shown to bind JUN in a phosphorylation-dependent manner (Bannister et al., 1995) . CBP coprecipitated with JUN in the absence of SP600125 but not in its presence (Figure 6c ). To exclude a general effect of SP600125 on GLI protein interactions, we used SUFU as control in HEK cells (Figure 6d ). These results indicate that the interaction of GLI2act and JUN depends on the phosphorylation of JUN by JNK, whereas suggesting differences in the interaction of GLI1 and GLI2act with JUN.
The positive effect of GLI on cell-cycle progression is dependent on JUN Recently, GLI1 and GLI2 were shown to promote cellcycle progression and antagonize contact inhibition in HaCaT keratinocytes (Regl et al., 2002) . We found activation of cell-cycle markers such as cyclin D1 and E2F1 by GLI2act and JUN (Table 1) , which prompted us to analyse whether GLI can stimulate S-phase entry in epidermal cells in the absence of JUN. We induced transgene expression in GLI2actHaCaT cells that were retrovirally transduced with either ctrlshRNA or JUNshRNA and determined bromodeoxyuridine (BrdU) incorporation at 48 h after confluence as an indicator of cell proliferation (Figure 7 ). Protein levels of GLI2 transgene and endogenous JUN were analysed by western blot (Figure 7c ). In the presence of JUN protein ( þ ctrlshRNA), induction of GLI2act expression led to a strong increase in BrdU incorporation from a basal level of approximately 10% BrdU-positive cells (Figures 7a and b) . In contrast, the cellcycle-promoting activity of GLI2act is significantly reduced upon JUN knockdown ( þ GLI2act/ þ JUNshRNA) (Figures 7a and b) , suggesting that cooperative activation of cell-cycle genes by GLI and JUN leads to enhanced cell proliferation that might have consequences for tumor formation and growth.
Discussion
Expression of GLI transcription factors in mouse epidermis can result in BCC whereas activation of Jun is required for papilloma formation in mouse skin (Young et al., 1999; Behrens et al., 2000) . Though the effects of these two oncogenes on skin are diverse, we show here a novel interaction between JUN and the GLI transcription factors leading to cooperative target gene regulation in human keratinocytes. JUN itself is a direct transcriptional target of GLI1 and GLI2, though GLI2act is a much more efficient activator of JUN transcription than is GLI1. This is not due to a generally higher activation potential as PTCH activation is comparable. Differences in target gene activation between GLI1 and GLI2act have previously been shown for other promoters (Regl et al., 2004b; Zhao et al., 2006; Eichberger et al., 2008) . GLI2act that shows enhanced transcriptional activation compared to fulllength GLI2 (Roessler et al., 2005) has been used as an 'activated GLI2' in vivo and in vitro. There is no evidence for the existence of the protein, though recently Speek et al. (2006) identified a GLI2 splice variant missing the N-terminal repressor domain in human gonadal tissue and several cell lines with comparable transcriptional activity in vitro. The JUN promoter contains at least one functional GLI-binding site as shown by mutation and consequent , lanes 1 and 4) whereas again, no interaction was detected for GLI1 and JUN (right lower panels, lanes 1 and 4). Proteins were precipitated with anti-FLAG agarose (FLAG) and detected by western blot with anti-MYC or anti-FLAG antibodies or a specific JUN antibody as indicated. Upper panels show protein levels in the input, and lower panels show precipitated proteins. FLAG-tagged SUFU was used as a positive control (left and right lower panels, lane 2) and the empty expression vector pCMV-FLAG (pCMV) as negative control (left and right lower panels, lane 3). (c and d) Interaction of GLI2act with JUN requires N-terminal phosphorylation of JUN. (c) MGLI2actHaCaT cells were induced for 24 h with doxycycline and treated with JNK inhibitor SP600125 or dimethyl sulfoxide (DMSO). CoIP of MGLI2act with endogenous JUN protein was carried out with a specific JUN antibody (aJUN). As control, normal mouse IgG (mIgG) was used. Western blot showed that interaction between JUN and MGLI2act can only be detected in DMSO-treated samples (lane 1). As positive control for a phosphorylation-dependent JUN interaction, we used CBP (lane 1). (d) Comparable results were obtained in transiently transfected HEK293FT cells (lanes 2 and 5). Cells were transfected with expression constructs as indicated. For precipitation, anti-FLAG agarose (FLAG) was used. To exclude a general effect of SP600125 on GLI2 protein interaction, we used FLAG-tagged SUFU (FSUFU) as positive control (lanes 1 and 4) . Input protein levels are shown in upper panels, and lower panels show immunoprecipitated proteins.
Cooperative target gene regulation by GLI and JUN S Laner-Plamberger et al loss of activation potential by GLI. When the AP-1 sites are mutated the activation by GLI is strongly reduced, whereas mutation of the GLI site does not affect relative activation by JUN. The requirement for JUN in GLIdependent promoter activation is also shown by shRNA-mediated JUN knockdown and through UV activation of endogenous JUN. In the latter case, the absolute level of transcription by JUN itself is greatly increased by concomitant GLI expression, revealing strong synergism between the two transcription factors. This is similar to interaction of TCF4 and JUN, also on the JUN promoter, as reported by Nateri et al. (2005) . The presence of the TCF-and JUN-binding sites greatly enhances activation by JUN and TCF4, whereas in the absence of the JUN sites activation by TCF4 is abolished (Nateri et al., 2005) . TCF4 and JUN have both been shown to bind directly the JUN promoter and interact physically. Similarly, GLI1 and GLI2 are recruited on the JUN promoter in the expected region and so is JUN. Physical interaction between JUN and GLI2 was detected by CoIP though surprisingly, no interaction was seen with GLI1. This may indicate that the interaction is too weak or transient to be observed by this method or that the lower activation potential of GLI1 on the JUN promoter is due to differences in the activation complex. JUN has been shown to interact with many other transcription factors and is a member of the wellcharacterized enhanceosome complex at the IFN-b promoter (Maniatis et al., 1998) where ATF-2/JUN, IRF-3 and IRF-7, and NF-kB (p50/RelA) are necessary for promoter activation. Several members of the complex including JUN are able to interact with CBP or p300. The binding sequences for these transcription factors are linearly arranged, in proximity or overlapping on the DNA whereas relatively few protein- Cooperative target gene regulation by GLI and JUN S Laner-Plamberger et al protein interactions are observed in the crystal structure (Panne, 2008) . JUN also frequently interacts with members of the ETS transcription factor family, which usually requires very close spacing for interaction to occur (Basuyaux et al., 1997; Kim et al., 2006) . A small distance between sites has also been reported for JUN-STAT3 interaction (Schaefer et al., 1995; Ginsberg et al., 2007) . It appears that such close spacing is not required for the functional interaction of TCF4 with JUN on the JUN promoter (Nateri et al., 2005) . In the case of the MYC and cyclin D1 promoters, an interaction of JUN, b-catenin and TCF4 does not even require an AP-1 site (Toualbi et al., 2007) . Similar to the interaction of TCF4 with JUN, interaction of GLI with JUN does not require close spacing, not only in the JUN promoter itself, but also in the other characterized JUN/ GLI-dependent promoters (Supplementary Figure S3 ; Supplementary Table S6) .
GLI2act itself does not necessarily interact directly with JUN but may be a member of a larger complex that includes CBP, a known partner of JUN (Bannister et al., 1995) and possibly other interactors of JUN. Physical interaction between JUN and GLI2, however, depends on N-terminal phosphorylation of JUN because it cannot be observed when the samples are treated with the JNK inhibitor SP600125. This implies the formation of a transcriptional activation complex enabled by phosphorylation of JUN, which then leads to cooperative activation of GLI/JUN target genes. Because JUN is activated in response to many stimuli such as the EGFR signal that has been shown to induce IL1R2 synergistically with GLI (Kasper et al., 2006b; Aberger F, personal communication) , it is tempting to speculate that JUN may act as an integrator of multiple inputs and is modulating the expression of HH/GLI target genes. Furthermore, our results show that JUN is also required for the cell-cycle-promoting activity of GLI in keratinocytes, suggesting that the JUN-GLI interaction may have important consequences for HH-dependent skin tumor formation.
Materials and methods
Cloning of promoter and expression constructs
For the JUN promoter reporter plasmid (JUNprom), a 1243 bp fragment of human JUN (NM_002228) was amplified by PCR (for primers see Supplementary Table S1 ) from human genomic DNA, digested with BlpI/XhoI and cloned into the luciferase reporter vector pGL3basic (Promega, Madison, WI, USA). Potential GLI-binding sites were mutated at positions 6 and 7 to G and AP-1-binding sites JUNBS1 and JUNBS2 were mutated as described in Angel et al. (1988b) and Stein et al. (1992) using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). GLI1, GLI2, GLI2act, GLI3act, JUN, SUFU expression constructs have been described previously (Schutte et al., 1989; Kogerman et al., 1999; Eichberger et al., 2008) .
Cell culture
HaCaT cells were cultured in Dulbecco's modified Eagle's medium (high glucose; PAA, Pasching, Austria) with 10% fetal calf serum (PAA), 100 mg/ml streptomycin and 62.5 mg/ml penicillin (Invitrogen, Carlsbad, CA, USA) at 37 1C, 5% CO 2 . N/TERT-1 cells were grown in Keratinocyte Serum-free Medium (Invitrogen) with 100 mg/ml streptomycin and 62.5 mg/ml penicillin, pFSK were cultivated in EpiLife basal keratinocyte medium (Invitrogen) supplemented with growth supplement (HKGS) (Invitrogen), 5% fetal calf serum (PAA), 100 mg/ml streptomycin and 62.5 mg/ml penicillin.
The T-REx System (Invitrogen) was used to generate MGLI1HaCaT and MGLI2actHaCaT double-stable cell lines expressing NLS-MYC-tagged human GLI1 or NLS-MYCtagged human GLI2act. For double-stable inducible HaCaT lines MGLI1HaCaT or MGLI2actHaCaT and GLI1HaCaT (Eichberger et al., 2006) or GLI2actHaCaT (Regl et al., 2004a) medium was supplemented with 25 mg/ml zeocin (Invitrogen) and 8 mg/ml blasticidin S (Sigma-Aldrich, St Louis, MO, USA). Transgene expression was induced by 50 ng/ml doxycycline (Sigma-Aldrich).
Retroviral gene expression and shRNA-mediated knockdown Lentiviral vectors used for expression of EGFP (LL3.7) (Rubinson et al., 2003) and EGFP-tagged GLI2act (LL3.7-GLI2act) are described in Kasper et al. (2007) .
For shRNA-mediated JUN knockdown, a single shRNA (TRCN0000039590) from the lentiviral MISSION shRNA set SHGLY-N2M_002228 (Sigma-Aldrich) and a nontarget control shRNA (SHC002) were selected. Virus production and infection of cells was performed essentially as described in Kasper et al. (2007) . At 24 h after virus infection, medium was supplemented with 1 mg/ml puromycin (Sigma-Aldrich) to select for infected cells. Doxycycline (Sigma-Aldrich) treatment (50 ng/ml medium) for transgene expression in GLI2actHaCaT cells was started 72 h after infection.
Cell proliferation assay
BrdU incorporation assays in shRNA-transduced GLI1Ha-CaT or GLI2actHaCaT were carried out as described (Regl et al., 2002) , using the FLUOS in situ cell proliferation kit (Roche, Basel, Switzerland). BrdU incorporation was detected with an Alexa Fluor 594-conjugated anti-BrdU mouse antibody (Invitrogen). Microscopic imaging was carried out on an Olympus IX 70 microscope equipped with a SPOT CCD camera (Diagnostic Instruments Inc., Sterling Heights, MI, USA). BrdU-positive cells and 4,6-diamidino-2-phenyl indole (DAPI)-stained nuclei were counted from two independent experiments carried out in triplicate.
RNA isolation, high-density DNA filter array production and qRT-PCR analysis Total RNA from BCC and normal skin was isolated with TRI Reagent (Molecular Research Center Inc., Cincinnati, OH, USA) followed by LiCl precipitation. Total RNA of HaCaT, N/TERT-1 and pFSK cells was isolated and purified with the High Pure RNA Isolation Kit (Roche). cDNA synthesis and qRT-PCR analysis were carried out as described in Eichberger et al. (2006) . Human large ribosomal protein P0 (RPLP0) was used for normalization of sample material in qRT-PCR analysis (Martin et al., 2001) . For primer sequences see Supplementary Table S2 . For expression profiling on cDNA filter arrays containing 2135 EST clones (Regl et al., 2004a) , cells were harvested after 72 h of doxycycline treatment, total mRNA was isolated and purified according to manufacturer's protocols (High Pure RNA Isolation Kit; Roche) and cDNA synthesized from 15 mg total RNA with Superscript II (RNase H À ) reverse transcriptase (Invitrogen) using oligo dT primers, according to manufacturer's instructions.
33 P-labeling of the cDNA, array production, hybridization and analysis were carried out as described earlier (Eichberger et al., 2006) .
Western blot and immunohistochemistry
Cells were lysed in 125 mM Tris (pH 6.8), 5% glycerol, 2% SDS, 1% b-mercaptoethanol, 0.006% bromophenol blue and proteins resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE). GLI and JUN were detected using the following primary antibodies: polyclonal goat-anti-GLI1 (GLI1-C18), polyclonal rabbit-anti-GLI2 (GLI2-H300), polyclonal rabbit-anti-JUN (JUN-H79), monoclonal mouse-antipJUN (p-c-JUN (KM1)) and polyclonal rabbit-anti-CBP (CBP-A22), all from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Secondary antibodies were HRP-conjugated goatanti-rabbit, chicken-anti-goat (Santa Cruz Biotechnology) and sheep-anti-mouse (GE Healthcare, Little Chalfont, UK). Proteins were visualized using the SuperSignal West detection system (PIERCE, Rockford, IL, USA). Paraffin-embedded sections of human BCC were stained for JUN as described (Eichberger et al., 2008 ) using a mouse monoclonal antibody directed against JUN (BD Biosciences, San Jose, CA, USA).
Luciferase reporter gene assay
HaCaT cells were grown in 24-well plates to 80% confluency, and transfected in triplicate with the respective expression constructs, shRNA constructs (ctrlshRNA or JUNshRNA) and pGL3 basic luciferase reporter plasmids. A lacZ expression plasmid was co-transfected for normalization. Transfection was carried out using SuperFect transfection reagent (QIAGEN Inc., Valencia, CA, USA) according to manufacturer's protocol. Luciferase activity in cell lysates was measured 48 h after transfection with a LucyII luminometer (Anthos Labtec, Cambridge, UK) using Luciferase Assay Substrate (Promega) according to manufacturer's instructions. UV irradiation of HaCaT cells was carried out with 750 kJ/m 2 using a Stratalinker 1800 UV crosslinker (Stratagene) 48 h after transfection, after additional 2 h of growth cells were subjected to the analysis.
Electrophoretic mobility shift assay and chromatin immunoprecipitation EMSA was carried out as described previously (Eichberger et al., 2008) . Oligonucleotides used for EMSA are shown in Supplementary Table S3 . ChIP from GLI1HaCaT or GLI2actHaCaT was carried out as described in Eichberger et al. (2008) . Antibodies used were monoclonal mouse-anti-JUN (BD Biosciences), polyclonal goat-anti-GLI2 (GLI2-N20), polyclonal goat-anti-GLI1 (GLI1-C18) and polyclonal rabbit-anti-CBP (CBP-A22), all from Santa Cruz Biotechnology. Control reactions were performed with species matched normal IgGs (Santa Cruz Biotechnology). PCR primer sequences are listed in Supplementary Table S4 .
Co-immunoprecipitation
For the detection of GLI1 or GLI2act protein interactions, MGLI1HaCaT and MGLI2actHaCaT cells were grown in 6-well plates and induced for 72 h. HEK293FT cells were grown in 6-well plates and transfected with expression construct using Transfectin (Bio-Rad, Hercules, CA, USA) according to manufacturer's instructions. For inhibition of JNK, the inhibitor SP600125 (Sigma-Aldrich) was added to a final concentration of 10 mM for 24 h, controls were treated with DMSO (Sigma-Aldrich).
CoIPs were carried out as described in Giesecke et al. (2006) with some modifications. Briefly all buffers were supplemented with protease inhibitor cocktail (Sigma-Aldrich) and Phos-STOP phosphatase inhibitor cocktail (Roche). Cells from three wells were pooled in cold buffer A (10 mM HEPES (pH 7.8), 1.5 mM MgCl 2 , 10 mM KCl, 20 mM ZnCl 2 ), homogenized and lysed in 10 volumes cold buffer B (150 mM NaCl, 50 mM Tris (pH 7.5), 0.1% SDS, 1% NP-40). Lysates were precleared with IgG Sepharose 6 Fast Flow (GE Healthcare) for 1 h Immunoprecipitation was carried out with 40 ml FLAGagarose (Sigma-Aldrich) or 4 mg of the following antibodies followed by adsorption to protein G Sepharose 4 Fast Flow (GE Healthcare): monoclonal mouse-anti-MYC (Santa Cruz Biotechnology), monoclonal mouse-anti-JUN (BD Biosciences) and normal mouse IgG as control (Santa Cruz Biotechnology). Precipitates were washed 3 Â with cold buffer B and proteins were eluted with 250 mM Tris (pH 6.8), 10% glycerol, 4% SDS, 2% b-mercaptoethanol and 0.006% bromophenol blue and subjected to SDS-PAGE followed by western blot analysis.
